Abstract
Purpose
Surgical removal of the primary tumor in metastatic prostate cancer (mPCa) is becoming a hotly debated issue. The purpose of this review was to summarize the current knowledge on cytoreductive radical prostatectomy (cRP) in this setting.
Materials and methods
We performed a non-systematic Medline/PubMed literature search of articles published in the field between January 2000 and April 2015.
Results
Cytoreductive surgery has demonstrated its benefit in various malignancies with a solid biological rationale to justify its assessment in mPCa. cRP appears as a safe and feasible procedure in expert hands and well-selected patients. A growing body of evidence suggests a survival benefit for patients undergoing cRP as a part of a multimodal approach compared to those treated with systemic treatment alone. Nevertheless, little is known about the best clinical and tumor characteristics for the selection of patients most likely to benefit from cRP. The current literature is based on retrospective studies with small cohorts and limited follow-up or large uncontrolled population-based studies.
Conclusions
Data from various other malignancies together with the biological rationale and preliminary results in PCa suggest that cytoreductive surgery may be an option in some mPCa patients. The lack of randomized controlled trials and the low level of evidence in the current literature preclude any firms conclusion on the benefit of cRP in mPCa. Ongoing phase II and future phase III studies are mandatory to define the exact role of cRP in mPCa and to identify the patients who are most likely to benefit from cRP.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479
Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 20(373):737–746
James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 19(387):1163–1177
Wiegand LR, Hernandez M, Pisters LL, Spiess PE (2011) Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int 107:1238–1242
Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 15(120):818–823
Bjurlin MA, Rosenkrantz AB, Beltran LS, Raad RA, Taneja SS (2015) Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol 12:617–628
Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 6(345):1655–1659
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 22(358):966–970
Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D (2004) Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 1(22):3475–3484
Nitta T, Sato K (1995) Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 1(75):2727–2731
Tzelepi V, Efstathiou E, Wen S et al (2011) Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 20(29):2574–2581
Resel Folkersma L, San Jose Manso L, Galante Romo I, Moreno Sierra J, Olivier Gomez C (2012) Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80:1328–1332
Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 1(66):11089–11093
Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 16(520):353–357
Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9:285–293
Kim MY, Oskarsson T, Acharyya S et al (2009) Tumor self-seeding by circulating cancer cells. Cell 24(139):1315–1326
Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 15(67):5033–5041
Ahmed M, Li LC (2013) Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 20:362–371
Verhagen PC, Schroder FH, Collette L, Bangma CH (2010) Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58:261–269
Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 24(373):301–308
Warde P, Mason M, Ding K et al (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 17(378):2104–2111
Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P (2012) Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62:213–219
Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A (2007) Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 15(67):1074–1081
Solberg A, Haugen OA, Viset T et al (2011) Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys 1(80):55–61
Kadmon D, Heston WD, Fair WR (1982) Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 127:1238–1242
Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H (1999) Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN + prostate cancer: a matched comparison. J Urol 161:1223–1227 (discussion 7–8)
Engel J, Bastian PJ, Baur H et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57:754–761
Steuber T, Budaus L, Walz J et al (2011) Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 107:1755–1761
Studer UE, Collette L, Sylvester R (2010) Can radical prostatectomy benefit patients despite the presence of regional metastases? Eur Urol 57:762–763 (author reply 3–5)
Messing EM, Manola J, Yao J et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472–479
Schroder FH, Kurth KH, Fossa SD et al (2004) Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846—a phase III study. J Urol 172:923–927
Swanson GP, Riggs M, Earle J (2004) Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation. J Urol 172:525–528
Thompson IM, Tangen C, Basler J, Crawford ED (2002) Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168:1008–1012
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 29(363):411–422
Qin XJ, Ma CG, Ye DW et al (2012) Tumor cytoreduction results in better response to androgen ablation—a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol 30:145–149
Heidenreich A, Pfister D, Porres D (2015) Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 193:832–838
Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058–1066
Fossati N, Trinh QD, Sammon J et al (2015) Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 67:3–6
Antwi S, Everson TM (2014) Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis. Cancer Epidemiol 38:435–441
Satkunasivam R, Kim AE, Desai M, et al (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol 194(2):378–385
Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 66:602–603
Won AC, Gurney H, Marx G, De Souza P, Patel MI (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–E255
Steinberg GD, Epstein JI, Piantadosi S, Walsh PC (1990) Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144:1425–1432
Grimm MO, Kamphausen S, Hugenschmidt H, Stephan-Odenthal M, Ackermann R, Vogeli TA (2002) Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 41:628–634 (discussion 34)
Le Scodan R, Stevens D, Brain E et al (2009) Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 20(27):1375–1381
Sooriakumaran P, Karnes J, Stief C, et al (2015) A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 69:788–794
Joniau SG, Van Baelen AA, Hsu CY, Van Poppel HP (2012) Complications and functional results of surgery for locally advanced prostate cancer. Adv Urol. 2012:706309
Loeb S, Smith ND, Roehl KA, Catalona WJ (2007) Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69:1170–1175
Acknowledgments
R.M. was supported by the Scholarship Foundation of the Republic of Austria—OeAD and by the EUSP Scholarship—European Association of Urology.
Authors’ contribution
Romain Mathieu, Stephan M. Korn, Shahrokh F. Shariat involved in protocol/project development, and data collection or management. Romain Mathieu, Stephan M. Korn, Shahrokh F. Shariat, Karim Bensalah, Gero Kramer contributed to data analysis. Romain Mathieu, Stephan M. Korn, Shahrokh F. Shariat, Karim Bensalah, Gero Kramer involved in manuscript writing/editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standards
This study was carried out in accordance with the principles of the ethical standards.
Rights and permissions
About this article
Cite this article
Mathieu, R., Korn, S.M., Bensalah, K. et al. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?. World J Urol 35, 567–577 (2017). https://doi.org/10.1007/s00345-016-1906-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-016-1906-3